Athenex, Inc.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, today announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer. “I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi. “The talent, experience, and in-depth knowledge that Luis and Pamela bring will be instrumental in the execution of our strategy at a time when Metagenomi is rapidly advancing multiple therapeutic programs towards clinical development. I am proud of the world-class team we have assembled, driven by our passion and commitment to develop curative therapeutics for patients using our proprietary, metagenomics-derived genome editing toolbox.” Dr. Luis Borges joins Metagenomi in the role of Chief Scientific Officer with more than 27 years of scientific and executive leadership experience in both biopharma and startup biotech companies. Dr. Borges was most recently Chief Scientific Officer at Century Therapeutics, where he successfully built a multifunctional discovery and translational research organization. Prior to Century, he served as Chief Scientific Officer at Cell Medica, Senior Vice President of Research at Five Prime Therapeutics, and Scientific Director in Amgen’s Therapeutic Innovation Unit. Dr. Borges brings scientific and operational rigor and decades of experience in drug development. This includes both discovery research and translational science, having helped to advance multiple drug development candidates from IND filing into clinical development and onward through FDA approval. In his role at Metagenomi, Dr. Borges will oversee the discovery and systematic advancement of the Company's next-generation gene editing technologies to accelerate their pathway to clinical translation for in vivo and ex vivo applications. Dr. Borges holds a Ph.D. in pathology from the University of Washington School of Medicine. Dr. Borges commented, “I am excited to join Metagenomi at this critical time where the company’s gene editing toolbox and preclinical programs are rapidly advancing. Our gene editing systems offer unique advantages to address genetic disorders driven by deletions, insertions, single-base-pair changes, and sequence repeats, that are found throughout the genome and across a variety of different cell types and organ systems. I believe Metagenomi is uniquely positioned to select the optimal tool to unlock the full potential of genome editing for patients suffering from serious illnesses.” Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles. Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech and medical technology companies including Diality, Capsida Biotherapeutics, and Graybug Vision, where she built the finance functions and led financial planning and strategy. As Chief Financial Officer at True North Therapeutics, Pamela completed preparations for an initial public offering before the company’s acquisition by Bioverativ. Prior to that, she served in various executive leadership roles at Amgen, including Corporate Treasurer and Vice President R&D Finance, where she was responsible for a $3 billion global R&D budget focused on advancing research and pipeline programs. Pamela holds an MBA from Columbia University and a BA in Economics from Wellesley College. “I’m thrilled to join Metagenomi at such a pivotal time for the company. With its strong financial foundation, I look forward to steering the company towards the next phase on its mission to develop curative gene editing therapeutics,” said Wapnick. About Metagenomi Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit ​metageno​mi​.co.

Portfolio focused on high-quality FDA approved products to treat patients in acute care hospitals, outpatient clinics and physician offices; pursuing 25+ new products over next two years Differentiated business model ensures supply chain resiliency through established manufacturing partner network Seasoned team with proven track record of launching critical medications includes Jeffrey Yordon, CEO Company to highlight expertise at CPhI Conference in Barcelona on October 24-26 SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on developing, manufacturing, and delivering critical medications, today announced its launch. Supported by a vast global network of development and manufacturing partners, Avenacy is prepared to meet the needs of today’s dynamic drug supply chain while ensuring quality of care to patients. Through a rigorous and optimized selection process, Avenacy is building out a portfolio of high-quality FDA approved products capable of delivering sustainable growth while providing reliability, safety, and convenience for customers. Products will cover a range of critical medications used to treat patients in various medically-supervised settings, from acute care hospitals to outpatient clinics and physician offices. All products will feature Avenacy’s unique packaging and labeling designed to assist healthcare providers with accurate medication selection, thereby supporting a reduction in administration errors and improper dosing. Avenacy will also provide ready-to-use formulations of essential medications to help address dosing inaccuracies, enhance patient safety, and streamline efficiency – all with the ultimate goal of improving patient care. “At Avenacy, we are advancing a partnership-driven business model that will enable us to be cost-efficient and nimble to market by focusing on product investment while minimizing manufacturing costs. With nearly 20 development and manufacturing partners already in place across five key geographies, we are well-equipped to begin fulfilling the needs of healthcare systems and providers,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “Our team brings a long-standing legacy in specialty pharmaceuticals and a reputation for prioritizing quality, safety, and reliability. Everything we do, from product selection to partner assessment and supply chain management, will be underpinned by an unwavering commitment to applying the highest industry standards, championing patient safety, and ensuring a dependable drug supply.” The Avenacy team and its founders Jeffrey Yordon and Kam Phulwani have a proven track record in building successful specialty pharmaceutical companies. The Company is led by Jeffrey Yordon, who previously served as COO of Athenex, Inc. and President of Athenex Pharmaceutical Division, a successful specialty injectable business that launched over 50 products and delivered nearly 40% CAGR revenue growth from 2017-2022. Before joining Athenex, Mr. Yordon founded and led Sagent Pharmaceuticals, a global specialty pharmaceutical company, which was ultimately acquired by Nichi-Iko Pharmaceuticals Company in 2016. Drawing on prior experience and success in specialty pharmaceuticals, Kam Phulwani made a significant investment to fund Avenacy and its expanding pipeline of products for the U.S. market. The management team brings over 245 collective years of industry experience spanning pharmaceutical development, quality, manufacturing, and sales. Avenacy is well-positioned to address key gaps in the U.S. drug supply landscape. The Company employs a multifaceted strategy incorporating rigorous quality standards, a global partnership model, and deep relationships across the drug development and manufacturing ecosystem, to ensure a dependable and resilient drug supply. Additionally, the industry has been increasingly plagued by shortage issues, with the number of active drug shortages peaking at 301 in the first quarter of 2023. As an essential medicines provider, Avenacy is committed to acquiring products historically facing lower supply, and has an open dialogue in place with the U.S. Food and Drug Administration (FDA) about products at risk for shortages. Avenacy will be showcasing its differentiated business model, diverse partner network, and experienced leadership team at this year’s CPhI 2023 Conference, taking place in Barcelona from October 24-26. During this time, the Company will be hosting meetings with potential partners, customers, and investors, as it continues to expand its global presence. About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on developing, manufacturing, and delivering critical medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit . View source version on businesswire.com: Contacts FTI Consulting Avenacy@fticonsulting.com Source: Avenacy View this news release online at:

NEW YORK, July 27, 2023 /PRNewswire/ -- The oncology drugs market is estimated to grow at a CAGR of 11.99% between 2022 and 2027. The market size is forecast to increase by USD 151.84 billion, according to Technavio. North America is estimated to contribute 44% to the growth of the global market during the forecast period. The US and Canada are the top revenue-generating countries in the North American market for cancer drugs. With the increasing adoption of minimally invasive surgery, the demand for cancer drugs is expected to rise in the region. Additionally, the growing prevalence of cancer in North America is further expected to drive the demand for oncology drugs during the forecast period. For Comprehensive details on the market size of the historical period(2017 to 2021) and forecast period (2023-2027) - View Sample report Continue Reading Technavio has announced its latest market research report titled Global Oncology Drugs Market Vendor Landscape The oncology drugs market is fragmented; the vendors are competing with competitors and are trying to get a greater market share. The market is growing, and the chances of new entrants cannot be overlooked. The major vendors have well-established economies of scale and market presence and generally rely on positioning technological advances, and the price of the products - The report provides a full list of key vendors, their strategies, and the latest developments. Buy Now Market Dynamics Major Drivers & Challenges- The growing focus on early detection of cancer is a key factor driving market growth. Despite cancer being a major global cause of death, there are advancements in identifying it early and improving outcomes for patients. Lung, liver, stomach, colorectal, breast, and esophageal cancers are prevalent among populations. Unhealthy lifestyle choices, poor diets, smoking habits, reduced pregnancies, and prolonged exposure to UV rays are factors contributing to the rise in cancer prevalence. Hence, a growing focus on early detection strategies is expected to drive market growth during the forecast period. The high cost of cancer treatment drugs is a major challenge hindering the growth of the oncology drugs market. The cost of chemotherapy can vary significantly based on several factors, such as the type of cancer, the severity of the illness, the treatment plan, and the patient's country of residence. Furthermore, these costs can be quite excessive for many patients, particularly those who lack health insurance or have limited financial resources. Moreover, expensive cancer treatment drugs can put a negative impact on healthcare systems and result in higher overall healthcare costs. Hence, the high cost of cancer treatment is expected to restrict market growth during the forecast period. Major Trends The rising adoption of immunotherapy is a major trend shaping the oncology drug market. Immunotherapy is a highly promising and rapidly advancing cancer treatment that focuses on activating the patient's immune system. It has shown high effectiveness, particularly for patients in advanced stages of the disease (third or fourth stages). New technologies are continuously being developed to improve the diagnosis, treatment, and overall management of cancer patients, especially in countries like India where cancer incidence is on the rise. Hence, the rising adoption of immunotherapy is expected to drive market growth during the forecast period. Technavio has identified key trends, drivers, and challenges in the market, which will help clients improve their strategies to stay ahead of their competitors. - View Sample Report Company Profiles The oncology drugs market report includes information on the product launches, sustainability, and prospects of leading vendors, including AbbVie Inc., Amgen Inc., Apikos Pharma, Arlak Biotech Pvt. Ltd., Aspen Pharmacare Holdings Ltd, Astellas Pharma Inc., AstraZeneca, Athenex Inc., Bayer AG, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Kremedine Health Pvt Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Bristol Myers Squibb Co. Competitive Analysis The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Market Segmentation The market is segmented by therapy (targeted therapy, immunotherapy, hormonal therapy, and chemotherapy), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The market share growth by the targeted therapy segment will be significant during the forecast period. Targeted therapy is a specialized form of chemotherapy that falls under precision cancer treatment. Unlike traditional chemotherapy, which affects a wide range of fast-growing cells throughout the body, targeted therapy drugs are specifically aimed at certain features present in cancer cells. The goal of targeted therapy is to target and inhibit the genetic characteristics of cells that control growth and differentiation, with the objective of stopping or slowing tumor development. Hence, these factors are expected to drive segment growth during the forecast period. Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports The orthodontic market is estimated to grow by USD 8,397.57 million at a CAGR of 17.13% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by product type (supplies and instruments), end-user segment (dental clinics, hospitals, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The high prevalence of oral disorders is a key factor driving the market growth during the forecast period. The statin market is estimated to grow by USD 2,676.61 million at a CAGR of 3.36% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by end-user (hospital, clinics, and others), type (synthetic statin and natural statin), and geography (North America, Asia, Europe, and the Rest of the World (ROW)). The rising prevalence of hypercholesterolemia is a key factor driving the market growth during the forecast period. Table of Contents 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global oncology drugs market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on global oncology drugs market 2017 - 2021 ($ billion) 4.2 Therapy Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ billion) 4.3 Distribution Channel Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ billion) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Therapy 6.1 Market segments Exhibit 30: Chart on Therapy - Market share 2022-2027 (%) Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%) 6.2 Comparison by Therapy Exhibit 32: Chart on Comparison by Therapy Exhibit 33: Data Table on Comparison by Therapy 6.3 Targeted therapy - Market size and forecast 2022-2027 Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ billion) Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ billion) Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%) 6.4 Immunotherapy and hormonal therapy - Market size and forecast 2022-2027 Exhibit 38: Chart on Immunotherapy and hormonal therapy - Market size and forecast 2022-2027 ($ billion) Exhibit 39: Data Table on Immunotherapy and hormonal therapy - Market size and forecast 2022-2027 ($ billion) Exhibit 40: Chart on Immunotherapy and hormonal therapy - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Immunotherapy and hormonal therapy - Year-over-year growth 2022-2027 (%) 6.5 Chemotherapy - Market size and forecast 2022-2027 Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ billion) Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ billion) Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%) 6.6 Market opportunity by Therapy Exhibit 46: Market opportunity by Therapy ($ billion) Exhibit 47: Data Table on Market opportunity by Therapy ($ billion) 7 Market Segmentation by Distribution Channel 7.1 Market segments Exhibit 48: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 49: Data Table on Distribution Channel - Market share 2022-2027 (%) 7.2 Comparison by Distribution Channel Exhibit 50: Chart on Comparison by Distribution Channel Exhibit 51: Data Table on Comparison by Distribution Channel 7.3 Offline - Market size and forecast 2022-2027 Exhibit 52: Chart on Offline - Market size and forecast 2022-2027 ($ billion) Exhibit 53: Data Table on Offline - Market size and forecast 2022-2027 ($ billion) Exhibit 54: Chart on Offline - Year-over-year growth 2022-2027 (%) Exhibit 55: Data Table on Offline - Year-over-year growth 2022-2027 (%) 7.4 Online - Market size and forecast 2022-2027 Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ billion) Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ billion) Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%) 7.5 Market opportunity by Distribution Channel Exhibit 60: Market opportunity by Distribution Channel ($ billion) Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ billion) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 63: Chart on Market share by geography 2022-2027 (%) Exhibit 64: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 65: Chart on Geographic comparison Exhibit 66: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ billion) Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ billion) Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ billion) Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ billion) Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ billion) Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ billion) Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion) Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion) Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ billion) Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ billion) Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 87: Chart on China - Market size and forecast 2022-2027 ($ billion) Exhibit 88: Data Table on China - Market size and forecast 2022-2027 ($ billion) Exhibit 89: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 Japan - Market size and forecast 2022-2027 Exhibit 91: Chart on Japan - Market size and forecast 2022-2027 ($ billion) Exhibit 92: Data Table on Japan - Market size and forecast 2022-2027 ($ billion) Exhibit 93: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.10 Germany - Market size and forecast 2022-2027 Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion) Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion) Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.11 UK - Market size and forecast 2022-2027 Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ billion) Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ billion) Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 103: Market opportunity by geography ($ billion) Exhibit 104: Data Tables on Market opportunity by geography ($ billion) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 105: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 106: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 107: Overview on factors of disruption 11.4 Industry risks Exhibit 108: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 109: Vendors covered 12.2 Market positioning of vendors Exhibit 110: Matrix on vendor position and classification 12.3 AbbVie Inc. Exhibit 111: AbbVie Inc. - Overview Exhibit 112: AbbVie Inc. - Product / Service Exhibit 113: AbbVie Inc. - Key news Exhibit 114: AbbVie Inc. - Key offerings 12.4 Amgen Inc. Exhibit 115: Amgen Inc. - Overview Exhibit 116: Amgen Inc. - Product / Service Exhibit 117: Amgen Inc. - Key offerings 12.5 Aspen Pharmacare Holdings Ltd Exhibit 118: Aspen Pharmacare Holdings Ltd - Overview Exhibit 119: Aspen Pharmacare Holdings Ltd - Business segments Exhibit 120: Aspen Pharmacare Holdings Ltd - Key offerings Exhibit 121: Aspen Pharmacare Holdings Ltd - Segment focus 12.6 AstraZeneca Exhibit 122: AstraZeneca - Overview Exhibit 123: AstraZeneca - Product / Service Exhibit 124: AstraZeneca - Key news Exhibit 125: AstraZeneca - Key offerings 12.7 Athenex Inc. Exhibit 126: Athenex Inc. - Overview Exhibit 127: Athenex Inc. - Product / Service Exhibit 128: Athenex Inc. - Key offerings 12.8 Bayer AG Exhibit 129: Bayer AG - Overview Exhibit 130: Bayer AG - Business segments Exhibit 131: Bayer AG - Key news Exhibit 132: Bayer AG - Key offerings Exhibit 133: Bayer AG - Segment focus 12.9 Bristol Myers Squibb Co. Exhibit 134: Bristol Myers Squibb Co. - Overview Exhibit 135: Bristol Myers Squibb Co. - Product / Service Exhibit 136: Bristol Myers Squibb Co. - Key news Exhibit 137: Bristol Myers Squibb Co. - Key offerings 12.10 Eli Lilly and Co. Exhibit 138: Eli Lilly and Co. - Overview Exhibit 139: Eli Lilly and Co. - Product / Service Exhibit 140: Eli Lilly and Co. - Key news Exhibit 141: Eli Lilly and Co. - Key offerings 12.11 F. Hoffmann La Roche Ltd. Exhibit 142: F. Hoffmann La Roche Ltd. - Overview Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments Exhibit 144: F. Hoffmann La Roche Ltd. - Key news Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus 12.12 GlaxoSmithKline Plc Exhibit 147: GlaxoSmithKline Plc - Overview Exhibit 148: GlaxoSmithKline Plc - Business segments Exhibit 149: GlaxoSmithKline Plc - Key news Exhibit 150: GlaxoSmithKline Plc - Key offerings Exhibit 151: GlaxoSmithKline Plc - Segment focus 12.13 Johnson and Johnson Services Inc. Exhibit 152: Johnson and Johnson Services Inc. - Overview Exhibit 153: Johnson and Johnson Services Inc. - Business segments Exhibit 154: Johnson and Johnson Services Inc. - Key news Exhibit 155: Johnson and Johnson Services Inc. - Key offerings Exhibit 156: Johnson and Johnson Services Inc. - Segment focus 12.14 Novartis AG Exhibit 157: Novartis AG - Overview Exhibit 158: Novartis AG - Business segments Exhibit 159: Novartis AG - Key offerings Exhibit 160: Novartis AG - Segment focus 12.15 Pfizer Inc. Exhibit 161: Pfizer Inc. - Overview Exhibit 162: Pfizer Inc. - Product / Service Exhibit 163: Pfizer Inc. - Key news Exhibit 164: Pfizer Inc. - Key offerings 12.16 Sanofi Exhibit 165: Sanofi - Overview Exhibit 166: Sanofi - Business segments Exhibit 167: Sanofi - Key news Exhibit 168: Sanofi - Key offerings Exhibit 169: Sanofi - Segment focus 12.17 Takeda Pharmaceutical Co. Ltd. Exhibit 170: Takeda Pharmaceutical Co. Ltd. - Overview Exhibit 171: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Key news Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 174: Inclusions checklist Exhibit 175: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 176: Currency conversion rates for US$ 13.4 Research methodology Exhibit 177: Research methodology Exhibit 178: Validation techniques employed for market sizing Exhibit 179: Information sources 13.5 List of abbreviations Exhibit 180: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio